The Raleigh, North Carolina-based company said it had a loss of 29 cents per share. Losses, adjusted for non-recurring costs, came to 10 cents per share.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 14 cents per share.
The specialty pharmaceutical company posted revenue of $14.2 million in the period, which met Street forecasts.
In the final minutes of trading on Thursday, the company's shares hit $3.69. A year ago, they were trading at $2.80.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BDSI at https://www.zacks.com/ap/BDSI
Copyright 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.